Skip to main content
Equibles
BCAB logo

BCAB · BioAtla, Inc. · Webcasts, Transcripts & Audio

Track BCAB — free

Use BCAB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BCAB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.69 -0.05 (-2.59%) At close · Aug 31
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management's assessment concluded that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the issuance date of these condensed consolidated financial statements.”
View the 10-Q filed Aug 13, 2026
Market Cap
$2.89M
Shares
1.67M
Volume · Aug 31 130.29K Avg daily vol (3M) 80.45K

BioAtla, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for BioAtla, Inc. (BCAB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$24.25M '22 Q1 22-05-04 ▼100% $ −$28.91M '22 Q2 22-08-09 · $ −$25.78M '22 Q3 22-11-03 · $ −$27.46M '23 Q1 23-05-11 · $ −$35.75M '23 Q2 23-08-01 LATEST · $ −$33.33M '23 Q3 23-11-07
Earnings call
FY25 · Q3
2025-11-13
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript
Confident tone Phase 3 OSV Registrational Trial (OPSCC) Market Opportunity / Commercial Prospects Mecbotamab Vedotin (MEK-V) / MECD Program
Diluted EPS
$-13.50
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript
Positive tone BA3182 EPCAM CD3 T-cell engager OSV (CAB-AXL ADC) head and neck cancer Conference presentations and data readouts
Diluted EPS
$-15.99
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2025-05-07
BioAtla, Inc. (BCAB) May 2025 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q1
2025-05-06
BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript
Positive tone Mecbotamab Vedotin (CAB-AXL-ADC) in mKRAS NSCLC and sarcoma Corporate partnerships and deal-making Evalstotug (CAB-CTLA-4) in melanoma
Diluted EPS
$-13.16
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
BioAtla, Inc. (BCAB) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript
Confident tone Ozuriftamab vedotin (CAB-ROR2-ADC) in head and neck cancer Evalstotug (CAP CTLA-4) in melanoma Cash runway and financing strategy
Diluted EPS
$-11.00
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript
Positive tone Evalstotug (CAB CTLA-4 antibody) safety and efficacy Ozuriftamab vedotin (CAB-ROR2-ADC) in head and neck cancer Mecbotamab vedotin (CAB-AXL-ADC) in NSCLC and KRAS
Diluted EPS
$-22.00
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript
Positive tone CAB-ROR2-ADC (ozuriftamab vedotin) in head and neck cancer CAB CTLA-4 antibody (evalstotug) dose escalation Nectin-4 ADC with carbohydrate linker
Diluted EPS
$-24.00
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-26
BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript
Confident tone BA3071 CAB-CTLA-4 antibody BA3021 CAB-ROR2-ADC BA3011 CAB-AXL-ADC
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript
Revenue
$
Diluted EPS
$-35.00
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
BioAtla, Inc. (BCAB) Q2 2023 Earnings Call Transcript
Revenue
$
Diluted EPS
$-37.50
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
BioAtla, Inc. (BCAB) Q1 2023 Earnings Call Transcript
Revenue
$
Diluted EPS
$-29.00
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
BioAtla, Inc. (BCAB) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
BioAtla, Inc. (BCAB) Q3 2022 Earnings Call Transcript
Revenue
$
Diluted EPS
$-34.50
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
BioAtla, Inc. (BCAB) Q2 2022 Earnings Call Transcript
Revenue
$
▼ 100% YoY
Diluted EPS
$-38.50
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
BioAtla, Inc. (BCAB) Q1 2022 Earnings Call Transcript
Revenue
$
Diluted EPS
$-32.50
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–16 of 16 webcasts
Key facts CIK 1826892 CUSIP 09077B203 Visit website Investor relations